Elenco degli articoli con argomento «dermatite atopica»

Dermatologia

10 ott 2023

Impact of Baricitinib on Patients'

The efficacy and safety of baricitinib for treatment of atopic dermatitis have been demonstrated in clinical trials

29 set 2023

Efficacy and safeness of tralokinumab in patients with atopic dermatitis

Efficacy and safeness of tralokinumab in patients with atopic dermatitis who developed conjunctivitis under dupilumab: A case series

14 set 2023

Real-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis

Atopic dermatitis (AD), a relapsing, inflammatory skin disease, is associated with pruritus that can negatively affect patients’ quality of life

31 ago 2023

Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib

Characterization of upadacitinib use and switching from dupilumab to upadacitinib among patients with moderate-to-severe atopic dermatitis (AD) is needed.

01 ago 2023

Lebrikizumab for the Treatment

Atopic dermatitis (AD) is a common, heterogeneous, inflammatory skin disorder

17 lug 2023

The differential effects of upadacitinib treatment on skin

Upadacitinib is an oral Janus kinase (JAK) 1 inhibitor approved in Japan for moderate-to-severe atopic dermatitis

03 lug 2023

Abrocitinib efficacy and safety in patients

Abrocitinib improved signs and symptoms of moderate-to-severe atopic dermatitis (AD) at 12/16 weeks in phase 3 studies with a manageable safety profile

05 giu 2023

Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis

Narrow-band (NB) UVB and UVA1 have been successfully used for the treatment of atopic dermatitis (AD) since the 1980s

04 mag 2023

Open day con consulti gratuiti in Abruzzo dalla parte della tua pelle navigation-next-alternate

La Campagna nazionale di sensibilizzazione sulla Dermatite Atopica promossa dai dermatologi SIDeMaST torna a Chieti e a l’Aquila.

04 mag 2023

Efficacy and safety of abrocitinib monotherapy in adolescents and adults

Differences in atopic dermatitis (AD) disease course and manifestation with age may extend to treatment response

17 apr 2023

In Lombardia open day sulla dermatite atopica navigation-next-alternate

Consulti gratuiti l'11 e il 18 marzo a Milano e Brescia

12 apr 2023

Al policlinico Federico II open day sulla dermatite atopica navigation-next-alternate

Sabato 11 marzo al policlinico Federico II

31 mar 2023

Open day dermatite atopica in tutta Italia navigation-next-alternate

L’11, 18 e 25 MARZO 2023 torna “Dalla parte della tua pelle”, la campagna Nazionale di sensibilizzazione sulla Dermatite Atopica dell’adulto.

14 mar 2023

Campagna nazionale di sensibilizzazione sulla Dermatite Atopica navigation-next-alternate

Torna la Campagna nazionale di sensibilizzazione sulla Dermatite Atopica. L'11, il 18 e il 25 marzo consulti gratuiti.

13 mar 2023

Prima Giornata dalla parte della tua pelle navigation-next-alternate

Dalla parte della tua pelle

20 feb 2023

A Review on the Safety of Using JAK Inhibitors in Dermatology

Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a spectrum of burdensome dermatologic conditions

20 feb 2023

Treatment of Severe Atopic Dermatitis with Dupilumab

Atopic dermatitis is a chronic inflammatory intensively pruritic skin disease.

17 feb 2023

Dalla parte della tua pelle navigation-next-alternate

Campagna SIDeMaST Prevenzione e cura della dermatite atopica: torna la campagna nazionale di sensibilizzazione sulla dermatite atopica dell’adulto edizione 2023

30 gen 2023

Prevalence of and association between atopic dermatitis

Atopic dermatitis (AD) and food allergy (FA) share similar type 2 inflammation and commonly co-occur

13 dic 2022

Comparison of real-world treatment outcomes of systemic immunomodulating

Few data exist on differences in treatment effectiveness and safety in atopic dermatitis patients of different skin types.